Diamedica Therapeutics Inc (DMAC)
US Market

Diamedica Therapeutics (DMAC) Stock Price & Analysis


DMAC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.12 - $3.17
Previous Close$2.75
Average Volume (3M)46.44K
Market Cap
Enterprise Value$41.03M
Total Cash (Recent Filing)$33.50M
Total Debt (Recent Filing)$469.00K
Price to Earnings (P/E)-4.7
Aug 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding11,956,874
10 Day Avg. Volume170,907
30 Day Avg. Volume46,436
Standard Deviation1.75
Financial Highlights & Ratios
Price to Book (P/B)2.75
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.98
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $1.12 and its highest was $3.17 in the past 12 months.
    What is Diamedica Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Diamedica Therapeutics Inc’s upcoming earnings report date?
    Diamedica Therapeutics Inc’s upcoming earnings report date is Aug 15, 2023 which is in 79 days.
      How were Diamedica Therapeutics Inc’s earnings last quarter?
      Diamedica Therapeutics Inc released its earnings results on May 15, 2023. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.04.
        Is Diamedica Therapeutics Inc overvalued?
        According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Diamedica Therapeutics Inc pay dividends?
          Diamedica Therapeutics Inc does not currently pay dividends.
          What is Diamedica Therapeutics Inc’s EPS estimate?
          Diamedica Therapeutics Inc’s EPS estimate is -$0.2.
            How many shares outstanding does Diamedica Therapeutics Inc have?
            Diamedica Therapeutics Inc has 26,933,727 shares outstanding.
              What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
              Diamedica Therapeutics Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went down -11.055%.
                Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
                Currently, no hedge funds are holding shares in DMAC


                Diamedica Therapeutics Stock Smart Score

                The Diamedica Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Diamedica Therapeutics Inc

                DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.


                Top 5 ETFs holding DMAC

                Market Value
                Smart Score
                iShares Core S&P Total U.S. Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold DMAC. The ETFs are listed according to market value of DMAC within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Acurx Pharmaceuticals
                Eledon Pharmaceuticals
                TRACON Pharmaceuticals
                Monopar Therapeutics Inc

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis